Seven technology appraisals (TAs) have been published by NICE, detailing evidence-based recommendations regarding whether the following drugs should be used for the specified indication:

TA477—Autologous chondrocyte implantation for treating symptomatic articular cartilage defects of the knee (this guidance replaces NICE TA89)

TA478—Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma

TA479—Reslizumab for treating severe eosinophilic asthma

TA480—Tofacitinib for moderate to severe rheumatoid arthritis

TA481—Immunosuppressive therapy for kidney transplant in adults (this guidance replaces NICE TA85)

TA482—Immunosuppressive therapy for kidney transplant in children and young people (this guidance replaces NICE TA99).

NICE TAs assess the clinical and cost effectiveness of health technologies, such as new pharmaceutical and biopharmaceutical products, as well as procedures, devices, and diagnostic agents. If the TA recommends a treatment as an option, the NHS must make sure it is available within 3 months (unless otherwise specified) of the TA publication date.